PS-341, a proteasome inhibitor, has been a first-line drug used in treating multiple myeloma for over a decade, which works by inhibiting intrinsic NF-κB activity by blocking IκBα degradation [37]. This evidence concerns the gene NFKBIA and plasma cell myeloma.